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Abstract (word count: 131/150) 
 
The burden of disease in infants and older adults due to respiratory syncytial virus 
(RSV) is receiving increasing recognition worldwide . Advances in knowledge of the 
structural biology of the RSV surface fusion (F) glycoprotein have revolutionized 
RSV vaccine development by providing a new target for preventive interventions. 
The RSV vaccine landscape has rapidly expanded to include 19 vaccine candidates 
and monoclonal antibodies (mAbs) in clinical trials, reflecting the urgency of 
reducing this global health problem and hence the prioritization of RSV vaccine 
development. Late phase RSV vaccine trial failures highlight gaps in knowledge 
regarding immunologic protection and provide lessons for future development. In 
this review we highlight promising new approaches to RSV vaccine design and 
provide a comprehensive overview of 19 RSV vaccine candidates and mAb’s 
currently in clinical development.
Introduction 1 
Respiratory syncytial virus (RSV) acute lower respiratory infection (ALRI) is 2 
increasingly being recognized as a global health problem with a high burden of 3 
disease and no vaccine licensed for prevention. In children under 5 years, it is 4 
estimated that 33.1 million episodes of ALRI, 3.2 million hospital admissions and as 5 
many as 118,200 deaths were attributable to RSV worldwide in 2015(1) [Figure 1]. 6 
Although often characterized as a pediatric disease, the burden of RSV in adults is 7 
also significant with a mortality rate of 7 to 8% among older adults hospitalized 8 
with RSV ALRI in the United States(2). Other estimates find a mortality rate 9 
attributable to RSV of 7.2 per 10,0000 person years in adults ≥65 years of age(3). 10 
RSV vaccine candidates aim to protect at least two target populations that are at risk 11 
for severe RSV disease: (1) young infants <6 months of age through maternal or 12 
pediatric (passive or active) immunization, and (2) older adults.  13 
Several opportunities but also challenges exist to development of an effective 14 
RSV vaccine. First, concerns of enhanced respiratory disease (ERD) following 15 
vaccination with the formalin-inactivated RSV (FI-RSV) vaccines in the 1960s have 16 
complicated the design and testing of RSV vaccines(4). ERD occurred in RSV-naïve 17 
infants who experienced infection with community-acquired wild-type RSV 18 
following receipt of FI-RSV. Decades of research have revealed that in these FI-RSV 19 
primed infants, natural RSV infection triggered a strong but non-neutralizing 20 
antibody response(5), followed by a T helper 2 (Th2) skewed immunologic 21 
response in animal models(6). The failure to mount a protective cytotoxic T 22 
lymphocyte (CTL) response was coupled with excess lung eosinophilia, with strong 23 
lung neutrophilia, monocytic infiltration, and immune complex deposition in the 24 
lung(7). Current vaccine candidates, especially those designed for RSV naïve infants 25 
and children, must demonstrate safety by avoiding these immunologic hallmarks of 26 
ERD. Second, an absolute correlate of protection against a clinically relevant RSV 27 
infection remains elusive, although cell-mediated immunity(8), mucosal IgA(9) and 28 
potent neutralizing antibodies(10) have been associated with decreased disease 29 
severity.  30 
Recently, three phase IIb/III trials (two vaccine trials in older adults(11,12) 31 
and one monoclonal antibody (mAb) trial in infants(13)) failed to meet clinical 32 
endpoints. The failure of these vaccine candidates demonstrates the continued gaps 33 
in knowledge regarding immunologic mechanisms of protection and qualitative 34 
aspects of protection in the different target populations.  Another challenge to RSV 35 
vaccine design is the lack of consensus regarding clinical endpoints of vaccine trials 36 
though attempts have been made to define these for prevention(14,15) and 37 
treatment trials(16). No definitive clinical endpoints have been articulated for 38 
vaccine or mAb trials by regulatory bodies and these endpoints may differ based on 39 
the target population. Finally, a major obstacle in RSV vaccine development is the 40 
limited protection conferred by immune responses elicited by natural RSV infection. 41 
Natural immunity provides only weak and transient protection against subsequent 42 
infection and re-infection occurs every three to ten years of life(17). In the pediatric 43 
population, the most severe RSV disease is usually observed during the primary 44 
infection; RSV disease during secondary infections is usually milder. An ideal RSV 45 
vaccine candidate should not only prevent severe disease in at risk populations, but 46 
should also interrupt community transmission and thereby provide secondary 47 
benefits in those who cannot benefit directly from vaccination.  48 
 Despite these obstacles, there are several opportunities for RSV vaccine 49 
development. First, the RSV disease burden has received increasing attention from 50 
international stakeholders such as the World Health Organization (WHO)(18) and 51 
the Bill & Melinda Gates Foundation based on better estimates of RSV-associated 52 
mortality worldwide(19). Second, the discovery of the structure and stabilization of 53 
the prefusion (pre-F) conformation of the RSV F protein has advanced the field by 54 
showing that pre-F specific antibodies may be more potent in protecting against 55 
RSV LRTI than antibodies targeting the postfusion (post-F) conformation and by 56 
thus providing a new target for vaccines and antibody therapies(20,21). Third, 57 
pharmaceutical companies have recognized the urgent unmet need of RSV 58 
prevention and prioritized the development of RSV antiviral drugs and vaccines.  59 
In 2015, a review of new RSV prevention and therapeutics was conducted 60 
which demonstrated that 10 vaccines were in clinical development(22). An update 61 
of that review is necessary in light of the number of new vaccine candidates as well 62 
as recent failures of vaccine candidates in the last several years.  In this review, we 63 
show that only 40% (4/10) of candidates from 2015 are currently continuing in 64 
clinical trials and 15 additional new vaccine candidates have entered clinical trials 65 
[Figure 2]. In the context of RSV as an increasingly recognized global health problem, 66 
these rapid changes and expansion show the prioritization of RSV vaccine 67 
development.  68 
69 
 70 
Methods 71 
A data collection template was designed for all vaccines in clinical development 72 
according to the PATH RSV Vaccine and mAb snapshot (updated November 2017 73 
(23)) [Supplementary Table 1]. Gaps in knowledge were identified by searching 74 
PubMed, clinical trial registries, WHO, European Medicines Agency (EMA) and 75 
pharmaceutical websites for each vaccine candidate, with no date or language 76 
restrictions, on Janurary 31, 2018(NM, ACL, NH, IR, EP, JS). We did not intend to do a 77 
systematic review of the literature. No inclusion or exclusion criteria were used. 78 
Instead, we selected articles that were most relevant to the subheadings used in this 79 
review as well as each vaccine candidate or mAb in clinical development. To 80 
supplement the data collected and the identified gaps in knowledge, data for this 81 
review were systematically collected using the data collection template 82 
[suppelemental table 1] at the RSV Vaccines for the World conference organized by 83 
the Respiratory Syncytial Virus Network (ReSViNet) from November 29 - December 84 
1, 2017 in Malaga, Spain. The goal of this meeting was to share scientific data and 85 
expertise on RSV vaccine development, and to connect stakeholders involved in RSV 86 
research. During the meeting information was collected (NM, ACL, NH, IR, EP, JS) 87 
from scientific presentations, posters and personal conversations. 88 
 We included all vaccine candidates and mAbs in clinical development 89 
according to the PATH RSV Vaccine snapshot and mAb snapshot. Vaccines were 90 
divided into four major groups: particle-based, vector-based, live-91 
attenuated/chimeric and subunit vaccines. Immunoprophylaxis with monoclonal 92 
antibodies was included as a fifth category. 93 
 94 
RSV Vaccine History 95 
RSV vaccine development started shortly after the first identification of the virus in 96 
humans in 1957(24). However, enhanced RSV disease upon natural infection with 97 
RSV after vaccination with a formalin-inactivated RSV (FI-RSV) candidate in RSV 98 
naïve infants resulted in 80% hospitalization and two deaths in the FI-RSV arm(4). 99 
This unanticipated result severely hindered inactivated virus and subunit vaccine 100 
development for many years, although work continued on development and human 101 
testing of live-attenuated RSV vaccine candidates. In the following 60 years, only 102 
two products were licensed for prevention of RSV: RSV intravenous 103 
immunoglobulin (RSV-IVIG, a polyclonal immunoglobulin preparation with high 104 
titers of anti-RSV neutralizing antibodies) was approved in the United States and 105 
Canada and discontinued after 2003 when replaced by palivizumab, a humanized 106 
monoclonal antibody directed against the RSV F glycoprotein(25,26). Since its initial 107 
approval in 1998, palivizumab is the only approved preventive intervention against 108 
RSV(26). Palivizumab has an excellent safety profile and is indicated for the 109 
prevention of severe RSV ALRI in children born prematurely, with congenital heart 110 
disease, or with bronchopulmonary dysplasia(27).  111 
A higher affinity variant of palivizumab, motavizumab, was developed early 112 
2000 but was withdrawn in 2010. In a head-to-head comparative trial motavizumab 113 
failed to show superiority to palivizumab for its primary endpoint (RSV-related 114 
hospitalization) because a small proportion of motavizumab recipients developed a 115 
mild skin reaction upon injection(28). However, in a placebo-controlled trial, 116 
motavizumab was highly efficacious against inpatient and outpatient RSV LRI in 117 
healthy term American Indian infants(29). Over the past 10 years development of 118 
preventive interventions for RSV has rapidly expanded.  119 
With respect to vaccines for active immunization, targeted for RSV naive 120 
children, many approaches were evaluated pre-clinically over the years, but based 121 
on pre-clinical results, only live-attenuated vaccine candidates were considered safe 122 
for clinical evaluation(30). Over the past 40 years, several biologically derived live-123 
attenuated vaccine candidates with attenuating temperature sensitivity or cold-124 
passage mutations were evaluated clinically, including in the pediatric population, 125 
but the appropriate balance of attenuation and immunogenicity, suitable for RSV-126 
naive children and infants, remained elusive. When reverse genetics techniques 127 
became available in the 1990’s, it became possible to design vaccine candidates with 128 
the appropriate level of attenuation, but with increased immunogenicity(31). While 129 
pediatric live-attenuated RSV vaccine candidates were under continued evaluation 130 
since the 1970’s there were few subunit vaccine trials conducted before 2000 except 131 
for the purified F vaccine(32). Over the past 10 years, vaccine development for RSV 132 
rapidly expanded. 133 
Currently, 19 vaccine candidates and mAbs for different target populations 134 
are in clinical trials, and many more in preclinical development(33).  135 
 136 
Lessons from the vaccine and mAb graveyard 137 
While vaccine development has accelerated, there have been three recent late-phase 138 
vaccine and mAb trial failures. It is important to distil lessons learned from these 139 
results to inform future vaccine development.  140 
1. A phase III double-blind, placebo-controlled trial (NURSERY) evaluating 141 
REGN2222, a mAb against RSV F protein, administered once or twice during 142 
the respiratory season in 1,149 healthy preterm infants over the age of 6 143 
months with a gestational age ≤35 weeks did not meet its primary endpoint to 144 
prevent medically-attended RSV infections through day 150 of life. REGN2222 145 
was accelerated from phase I to phase III due to promising results and the FDA 146 
granted Fast Track designation in October 2015. REGN2222 targeted antigenic 147 
site V on the RSV pre-F protein, a major target for high-potency mAbs(34). The 148 
basis for failing to meet the primary clinical endpoint is not yet known as 149 
analyses of this late-stage failure have not yet been made public. 150 
2. The second candidate that failed to meet the predefined study endpoint in 151 
phase III clinical trials was the RSV F nanoparticle vaccine candidate for older 152 
adults, a candidate based on aggregates of full-length post-F. The results of the 153 
preceding phase II RSV F nanoparticle trial suggested the candidate vaccine 154 
might have modest efficacy. In the phase III trial, 11,586 subjects ≥60 years of 155 
age were enrolled in 60 US sites in a double-blind placebo-controlled trial 156 
(RESOLVE) over a single season starting November 2015 with 330 days 157 
follow-up. Although the vaccine showed promising results in phase II and 158 
comparable immunogenicity measures in the two phases as determined by 159 
neutralizing and palivizumab competing antibody induction, the vaccine failed 160 
to show efficacy against RSV moderate–severe lower respiratory tract disease 161 
(ms-LRTD) in phase III results(12). Compared to the previous season, RSV 162 
acute respiratory disease (RSV-ARD) and ms-LRTD attack rates were lower 163 
than expected in the 2015 – 2016 season (RSV-ARD: 2.0% versus 4.9% and 164 
RSV-msLRTD 0.4% versus 1.8%). The pharmaceutical company attributes the 165 
difference in vaccine efficacy observed to the lower attack rate(35). In a post-166 
hoc subgroup analysis, the vaccine candidate showed efficacy against 167 
hospitalizations for chronic obstructive pulmonary disease (COPD) 168 
exacerbations from all causes(35). Upon further analysis of the phase III 169 
results, there was a trend towards higher RSV microneutralization titers in 170 
adults without RSV-ARD when compared to adults with RSV-ARD. One 171 
conclusion that can be drawn from this trial is that late-phase clinical research 172 
for an RSV vaccine candidate requires evaluation across more than one RSV 173 
season.  174 
3. Development of the MEDI-7510 vaccine candidate, a subunit vaccine candidate 175 
for older adults, was discontinued after a phase IIb trial in North America, 176 
Europe, South Africa, and Chile in 1900 adults ≥60 years after the study failed 177 
to meet its primary objective. MEDI-7510 was a subunit vaccine using soluble 178 
(unagreggated) postfusion (post-F) conformation of the F protein with a TLR4 179 
agonist adjuvant which showed safety and immunogenicity in phase I clinical 180 
trials with elevated B and T cell responses in the vaccine group compared to 181 
the placebo group(36). The incidence of RSV-associated ARI as diagnosed by 182 
PCR was 1.7% and 1.6% in the vaccine and placebo groups, respectively, for a 183 
vaccine efficacy (VE) of -7.1%. In secondary analyses in subsets of the study 184 
population, no efficacy was found. On day 29, 93% of vaccinees had an anti-F 185 
antibody seroresponse(36).  Possibly the choice of a post-F antigen which 186 
induced largely non-neutralizing antibodies failed to induce effective 187 
protective immunity(37) Other proposed explanations upon further analysis 188 
include a low incidence of the lab-confirmed RSV in the study population or 189 
alternatively selection of the study population which included high-risk and 190 
low-risk older adults.  Considerations for the future may be to select an older 191 
study population that is at higher risk of RSV infection. 192 
 193 
Vaccine antigens 194 
Vaccine antigens employed by RSV vaccine candidates are diverse. The majority of 195 
vaccines in clinical trials (11/18) utilize the F protein, a class I viral fusion protein, 196 
as an antigenic target. The RSV F protein is highly conserved and facilitates viral 197 
fusion with host cells along with the hallmark formation of syncytia. An 198 
understanding of the structural differences between pre-F and post-F 199 
conformations as well as stabilization of the pre-F soluble forms has resulted in 200 
advances in the design of vaccine antigens(21,38). Current vaccines use pre-F and 201 
post-F as vaccine antigens[Table 1]. Antigenic sites specific to pre-F, post-F and 202 
those shared by both conformations are targeted by antibodies with differing 203 
neutralization capacity. After isolation of a large number of mAbs from adults and 204 
infants, the F protein has been divided into six non-overlapping antigenic sites with 205 
varying neutralization potency (sites Ø–V)(34). The most potent neutralizing 206 
antibodies target pre-F antigenic sites. For example, antigenic site Ø is located at the 207 
apex of the pre-F conformation, one of the most variable regions of the F 208 
protein(21). The epitopes shared by both pre-F and post-F conformation are site II 209 
(the palivizumab-binding site) and site IV(39). Of note, the predominant 210 
conformation displayed on FI-RSV vaccine candidate was the post-F 211 
conformation(40). There is no consensus on the trigger for the pre-F to post-F 212 
conformational change making it difficult to ensure a vaccine antigen maintains a 213 
pre-F conformation. Assays to assess antigen conformation are needed. Likewise 214 
there is no consensus on cellular receptors that determine viral tropism(41).  215 
 Other vaccine antigens, used alone or in combination, less frequently contained in 216 
RSV vaccine candidates include the RSV envelope associated glycoproteins for 217 
attachment (G) (1/18) and small hydrophobic protein (SH) (1/18) as well as internal 218 
proteins: nucleocapsid (N) (3/18), matrix (M) (1/18), and M2-1 (1/18). Besides the F 219 
protein, the G protein is the other target for neutralizing antibodies on the viral surface. 220 
The G protein is the most important protein in viral attachment of RSV. G is a less 221 
frequently utilized viral antigen in vaccines due to high variability(42) across RSV strains 222 
and limited knowledge of its surface structure(43). G protein exists as an oligomer on the 223 
surface of RSV particles and as a monomer when secreted from infected cells in as a 224 
soluble form(44). There is evidence that the soluble form of G protein can act as a decoy 225 
that helps the virus evade the antibody response(45). The role of the SH protein of RSV 226 
is not well understood, but has been observed to play a role in viral replication in vivo(41) 227 
and inflammasome activation(46). The SH protein contains a transmembrane and 228 
extracellular domain(47); the latter has been used as a vaccine antigen(48). Internal 229 
proteins are particularly relevant to induce T cell-mediated immunity(43). Three non-230 
membrane RSV proteins have been included in RSV vaccine design. The N protein is the 231 
major nucleocapsid protein that encapsidates the RNA genome of the virus(49). The M2-232 
1 and M2-2 proteins are specific to RSV and other Pneumoviridae. M2-1 is an essential 233 
protein for viral transcription (50). Finally, the M protein is a membrane-associated 234 
protein which is important for formation of the viral envelope(51). Other non-structural 235 
proteins such as NS1 and NS2 have also been incorporated in preclinical vaccine 236 
candidates. These proteins counteract interferon induction and effector functions 237 
and may also affect adaptive immune responses. In summary, different viral proteins 238 
are being employed as antigens in RSV vaccine design. Viral surface glycoproteins such 239 
as F and G are known to induce antibodies with differing neutralization capacity, SH 240 
protein may be important to induce antibody dependent cell-mediated  cytotoxicity 241 
(ADCC) whereas non-membrane proteins are especially important to induce a robust T 242 
cell response(43). 243 
 244 
Target populations 245 
RSV prophylactic interventions should be designed to protect at least two 246 
populations most vulnerable for severe RSV disease: young infants and older adults, 247 
although there are certainly other important high-risk target populations to 248 
consider. However, a vaccine that can prevent infection in pregnant mothers, 249 
caregivers of children (health professionals and teachers), school age children and 250 
older adults would prevent RSV colds and potentially interrupt community 251 
transmission. It is estimated that 45% of hospital admissions and in-hospital deaths 252 
due to RSV-ALRI occur in infants younger than 6 months of age(1), an age at which 253 
vaccines are generally less immunogenic. Older adults and adults with chronic 254 
cardiopulmonary conditions have emerged as an important target for RSV 255 
prevention due to an increased understanding of RSV burden in this population. An 256 
overview of all RSV vaccine candidates per target population is shown in Table 2. 257 
 Maternal vaccination is employed to passively immunize young infants by 258 
boosting maternal antibody titers that are transferred to the infant, thereby 259 
extending the period of protection conferred by maternal antibodies. Historically, 260 
epidemiologic studies have demonstrated an association between higher maternal 261 
RSV antibody concentrations and protection from lower respiratory tract infection 262 
in infants(52). Passive transfer of antibodies to infants has been shown to be 263 
protective against severe RSV infection through the administration of high-titer 264 
polyclonal and monoclonal antibodies (RSV-IVIG and palivizumab) (25,26). The 265 
proof-of-principle of maternal vaccination as a tool to prevent infant disease has 266 
been demonstrated by the effective eradication of maternal and neonatal tetanus 267 
worldwide through tetanus toxoid vaccination in pregnancy(53) Maternal 268 
vaccination may also play a role in prevention of RSV infection in pregnant women 269 
and prevention of adverse birth outcomes, however the burden of RSV disease in 270 
pregnant women is not yet well-established.  271 
 Premature infants, a population known to be at high risk for severe RSV 272 
disease, may be insufficiently protected by maternal vaccination given that the 273 
majority of transport of IgG via the placenta occurs after 32 weeks gestational 274 
age(54). Globally 10% of children are born preterm(55). The burden is especially 275 
relevant in low and middle-income countries (LMICs) as more than 60% of preterm 276 
birth occurs in Sub-Saharan Africa and South Asia(56). Thus, a maternal vaccination 277 
strategy may not be sufficient to protect the high-risk preterm population. Other 278 
populations in which impaired transplacental antibody transfer may limit 279 
protection by maternal vaccination include infants of mothers with chronic infection, 280 
hypergammaglobulinaemia, malaria, and HIV infection(57). The ratio of 281 
transplacental antibody transfer and antibody decay kinetics are currently 282 
considered the main parameters to assess protection conferred via maternal 283 
vaccination. However, protection may also be mediated by breast milk antibodies 284 
transferred postnatally.  285 
 A combined strategy that utilizes maternal vaccination to protect young 286 
infants followed by pediatric vaccination may be an effective strategy to prevent 287 
severe RSV infection in young children. This strategy is estimated to avert at least 288 
twice as many admissions per 100 births and four times as many in-hospital deaths 289 
per 1000 births than maternal vaccination alone(58). A combined strategy will be 290 
particularly relevant to prevent morbidity and mortality in children with 291 
comorbidities who are at risk of severe RSV disease at older ages (59,60). A similar 292 
maternal and pediatric combined immunization strategy is currently employed for 293 
pertussis and influenza vaccination(57).  294 
 Although RSV is frequently considered a pediatric pathogen, it is important 295 
to consider the older adult population with regard to prevention of severe RSV 296 
disease. RSV has been identified as an important disease in older and high-risk 297 
adults, with a disease burden similar to that of influenza(2). It is estimated that RSV 298 
accounts for 10,000 – 14,000 deaths in adults over the age of 65 years in the United 299 
States(2,3). In addition, older adults with comorbidities such as underlying heart or 300 
lung disease are at elevated risk of severe RSV disease; RSV infection develops in 4-301 
10% of high-risk adults annually(2). 302 
 303 
Immunologic endpoints 304 
Antibodies are thought to be the key player in limiting RSV ALRI as evidenced by 305 
proven protection in immunoprophylaxis trials in children (25,26,29). Recent 306 
evidence from experimental human infection shows a protective role for nasal RSV-307 
specific IgA against RSV infection(9), underscoring the importance of mucosal 308 
immunity. An inability to generate memory IgA responses after RSV infection is 309 
thought to be in part responsible for incomplete immunity and subsequent RSV re-310 
infection. Antibodies directed against different antigenic sites of the F protein 311 
display different neutralization capacity with the most neutralization-sensitive 312 
epitopes exclusive to the pre-F conformation. Antibodies with specificity for 313 
antigenic sites Ø and V show high neutralizing activity and are exclusive to the pre-F 314 
conformation(34,61). Antibodies against antigenic site III prefer the pre-F 315 
conformation and exhibit high neutralizing activity(62). Antibodies directed against 316 
site II and IV, present on both pre-F and post-F, exhibit medium to high 317 
neutralization potency(61,63). Finally, antibodies against antigenic site I, present 318 
primarily on post-F, show weak or no neutralization. Escape mutants of these 319 
antigenic sites have been identified, but global RSV genetic data are needed to assess 320 
the molecular heterogeneity of RSV and the subsequent susceptibility or resistance 321 
to monoclonal antibodies targeting RSV among circulating viruses. A measure of 322 
functional antibody response can be elucidated by the ratio of total RSV-binding 323 
antibodies to RSV-neutralizing antibodies (ELISA-to-neutralization ratio). A ratio of 324 
less than one may be an important correlate of protection(64). Furthermore, rather 325 
than a definitive protective threshold for antibodies, fold-rise in antibody titer may 326 
be a relevant correlate of protection. 327 
 Many different immunologic assays are employed in clinical trials. 328 
Neutralizing activity of serum is a frequent immunologic endpoint of vaccine trials. 329 
Recent efforts by PATH, the WHO, and the National Institute for Biological Standards 330 
and Control (NIBSC) examined the variability of RSV neutralization assays across 331 
laboratories and recommended steps for improved standardization globally(65), 332 
resulting in the development of a new RSV international antibody standard now 333 
available through the NIBSC(66). For other frequently used immunologic assays 334 
such as palivizumab-competing antibodies (PCA), ELISA and T cell assays no such 335 
standardization has taken place yet. 336 
 Once infection of the lower airways is established, CD8 T cells play an 337 
important role in viral clearance(67). Th2-biased responses have been associated 338 
with RSV ERD and measurement of Th1 and Th2 responses are important to  predict 339 
safety of a vaccine candidate in clinical trials in young children.  340 
 We highlight the different aspects of the expected immune response (pre-F 341 
immunity, general immunity, herd immunity, mucosal/systemic immunity) for all 342 
19 vaccine candidates in Table 3. A definitive threshold for protection against RSV 343 
disease remains elusive. Ultimately, the outcome of large-scale vaccine trials will 344 
inform which immunologic measures correspond to protection from clinical RSV 345 
disease. 346 
 347 
Vaccine strategies 348 
We have divided vaccines in clinical development into four categories in accordance 349 
with the PATH RSV vaccine and mAb snapshot: particle-based, vector-based, subunit 350 
and live-attenuated/chimeric vaccines(23). We have also included mAbs in clinical 351 
development for the prevention of RSV ALRI. In the snapshot there are 43 vaccines 352 
and 4 mAbs in development of which 19 are in clinical stage development. An 353 
important consideration for all vaccines is not only to prevent severe RSV disease, 354 
but also to avoid any and all risk of priming for RSV ERD. Per our current 355 
understanding of the underlying mechanisms leading to RSV ERD, this would 356 
preclude the use of protein-based vaccines in RSV naïve children and infants, and it 357 
is unknown whether replication deficient vectors, engineered to express RSV 358 
antigens intracellulary, would be safe in this population. In Table 1 we provide a 359 
comprehensive overview and more detailed comparison of all characteristics of the 360 
19 vaccine candidates and mAbs in clinical development. 361 
 362 
Particle-based vaccines 363 
The RSV F nanoparticle-based vaccine platform is currently being evaluated for 364 
protection of three target populations: (1) infants through maternal vaccination, (2) 365 
children between 2 months and 5 years, and (3) older adults. These vaccine 366 
candidates utilize aggregates of a modified stabilized F surface protein which 367 
exhibits the post-F morphology(68). The maternal RSV F nanoparticle vaccine 368 
candidate is farthest along in clinical development and the PREPARE trial has 369 
entered the third year global season of phase III research to enroll up to 8,618 370 
pregnant women at 80 sites in 11 countries(35). Second in clinical development is 371 
the RSV F nanoparticle vaccine for older adults. Despite lack of efficacy in a phase III 372 
trial (RESOLVE) with a non-adjuvanted vaccine candidate, development was 373 
continued in a phase II roll-over study initiated in January 2017 in Australia in 300 374 
adults. The aim of this rollover trial is to determine whether 2 dose regimens with 375 
an adjuvant (Matrix-M or aluminum-phosphate) may increase the magnitude and 376 
quality of the immune response in older adults. The results from the RESOLVE trial 377 
in older adults vaccine suggested vaccine efficacy in adults with COPD, leading to 378 
considerations to initiate a future trial in this older adult population at high risk for 379 
severe RSV infection(35). Finally, the phase I trial was completed in young children 380 
24-72 months of age in 2016, but no data have been published so far(69). 381 
SynGEM is a particle-based needle-free mucosal vaccine containing the RSV F 382 
protein as vaccine antigen attached to empty bacterial particles made from 383 
Lactococcus lactis. The platform in which an antigen is presented by a bacterial 384 
particle has shown both local and systemic antibody responses for the influenza 385 
candidate in clinical trials using the same platform(70) but needs further 386 
optimization for RSV vaccination. The preliminary results of immunogenicity testing 387 
have been reported. The immunogenicity of this vaccine was evaluated after 388 
delivery as a nasal spray to healthy adult volunteers. Two intranasal doses of 389 
SynGEM were administered 28 days apart at low or high dose, 24 subjects per group 390 
(6 of each group receiving placebo, double blinded). Assays of serum virus 391 
neutralization, RSV F-specific antibody, palivizumab-like antibody and F-specific IgA 392 
indicated some immunogenicity, but the results did not reach the threshold set for 393 
continuation to viral challenge and the studies were suspended in 2017. 394 
 395 
Vector-based vaccines 396 
There are five vector-based vaccines in clinical development. Four of these vaccine 397 
candidates employ an adenovirus vector to display viral antigens and the fourth 398 
uses a modified vaccinia virus Ankara (MVA), a replication-defective smallpox viral 399 
vector. The MVA vector has been safely used in vaccines for other infectious 400 
diseases(71). The vaccine candidate, MVA-BN-RSV, induces both a humoral and cell-401 
mediated response by displaying four viral antigens: F, G, N and M2-1. Phase II 402 
results in healthy older adults from this candidate will soon be announced. 403 
Preclinical studies in calves with chimpanzee adenovirus PanAd3-RSV and MVA-RSV 404 
vectored RSV vaccines both induced neutralizing antibodies and cellular immunity, 405 
with no evidence of ERD(72), and have supported continued evaluation in human 406 
clinical trials(73). Phase I results showed that both vectors were safe in healthy 407 
adults. However, MVA-RSV induced an increased T-cell response compared to 408 
PanAd3-RSV. 409 
 The second vector-based vaccine candidate, VXA-RSV-f, uses an innovative 410 
platform using an adenovirus 5 based oral tablet delivery platform that is stable at 411 
room temperature. The results from preclinical studies show that mucosal 412 
immunization with the oral vaccine candidate enhanced mucosal IgA in the upper 413 
airways. Preclinical studies in cotton rats with VXA-RSV-f found greater respiratory 414 
humoral immune responses to RSV infection as measured by lung IgA and lung IgG 415 
when comparing vaccination with this vaccine candidate via the intranasal or oral 416 
route to intranasal RSV infection. Given that severe disease in the older adult 417 
population is thought to be mediated by immunosenescence characterized by 418 
impaired T cell response, this vaccine candidate, which induces a mucosal humoral 419 
response, may be a promising intervention for the older adult population(74). 420 
 Third and fourth, Ad26.RSV.preF, is a vaccine candidate being developed for 421 
two populations: the older adult population and the pediatric population. The 422 
candidate uses pre-F antigen expressed in the human adenovirus strain 26, which 423 
has a favorable safety profile when used for other infectious diseases(75,76). The 424 
first vaccine candidate in development used post-F as antigen (FA2) but has now 425 
changed to stabilized pre-F conformation. The stabilized pre-F protein has 5 amino 426 
acid changes from wild-type, and is stable at 4C and heat-stable(38). With the 427 
expectation that this vaccine candidate will induce highly neutralizing antibodies 428 
against pre-F, phase II will be initiated in RSV-seropositive pediatric populations. In 429 
December 2017 a phase II trial has been initiated comparing influenza vaccination 430 
with RSV and influenza co-administration in healthy older adults(77). 431 
 Fifth, ChAd155-RSV, a replication-incompetent chimpanzee adenovirus 155 432 
has been used as a vector for the F, N and M2.1 antigens. The anticipated use for this 433 
pediatric vaccine is to start immunization at two months of age, and to use two to 434 
three doses, routinely instead of seasonally, alongside the normal pediatric 435 
vaccination schedule. The vaccine candidate is currently being evaluated in 12-23 436 
month old RSV seropositive children. In the future, there are plans to perform 437 
clinical trials in seronegative children sequentially from older to younger ages (12-438 
24 months followed by 6-12 months and subsequently 2-6 months of age) in order 439 
to ensure safety in RSV-naïve populations. Results of phase II trials are expected to 440 
be announced in 2020.  441 
In summary, vector-based vaccines are used to display various RSV viral 442 
antigens and three of these vaccine candidates are in phase II trials. 443 
 444 
Subunit vaccines 445 
Due to concerns of ERD for protein-based vaccines, subunit vaccines are only in 446 
development for pregnant women and older adult populations. The subunit vaccine 447 
candidate furthest in development is the GSK RSV F vaccine, which uses a stabilized 448 
version of soluble secreted F protein engineered to preferentially maintain the Pre-F 449 
conformation. Phase I results demonstrated safety and immunogenicity as 450 
evidenced by RSV neutralizing antibody response in healthy men(78). However, a 451 
phase II trial scheduled for 2017 was halted due to instability of the pre-F antigen 452 
during manufacturing. 453 
 Structure-guided stabilization of the pre-F conformation of F protein has 454 
yielded a subunit vaccine candidate, DS-Cav1. The stabilization includes a foldon 455 
trimer, the introduction of cysteine residues, and cavity-filling hydrophobic 456 
residues(79). The vaccine is able to preserve neutralization-sensitive epitopes on a 457 
functional pre-F form of the viral surface protein. In preclinical studies the subunit 458 
vaccine induced high levels of RSV-neutralizing antibodies in mice and non-human 459 
primates(79). Preliminary results from the phase I trial, VRC 317, will soon be 460 
published. However site Ø has the most natural genetic variability of all the 6  461 
described antigenic sites on the F protein, and it remains to be seen whether this 462 
will result in more rapid development of resistance mutations to the vaccine. 463 
 DPX-RSV is a vaccine candidate with a unique choice of vaccine antigen, the 464 
extracellular domain of the SH protein of RSV(48). The DepoVax technology allows 465 
for a prolonged exposure of antigen and adjuvant, and aims to induce ADCC using a 466 
liposome and oil-based depot(80). The antigen and adjuvant are encapsulated in a 467 
liposome, lyophilized and suspended in oil and the process is expected to produce 468 
vaccines with long shelf-life stability(81). Phase I results on safety and 469 
immunogenicity in the older adult population will soon be published from an 470 
investigator-initiated study. 471 
 472 
Live-attenuated and chimeric vaccines 473 
In the context of historical concerns for enhanced RSV disease, live-attenuated 474 
vaccines can be considered safe for RSV naïve infants, based on consistent clinical 475 
study results showing that these candidates do not prime for ERD following 476 
subsequent exposure to wild-type RSV after vaccination(82). Another benefit of live-477 
attenuated vaccines in the pediatric population is their ability to generate an 478 
immune response despite the presence of maternally-acquired antibodies, and to 479 
elicit a more broad antibody and cellular response(31). Live-attenuated vaccines are 480 
likely limited to the young infant population as pre-existing immunity in older 481 
populations might not permit sufficient replication to generate protective immune 482 
responses. Safety is a general concern of live-attenuated vaccines that are delivered 483 
intranasally, in particular if attenuation is insufficient.  484 
 Five live-attenuated vaccine candidates in phase I clinical trials are being 485 
developed in partnership with the National Institutes of Health (NIH).  Live-486 
attenuated vaccines face the challenge of achieving sufficient attenuation to be safe 487 
while remaining immunogenic enough to induce a protective immune response. 488 
Improved understanding of the RSV viral genome has informed the development of 489 
new vaccine candidates. Two main modifications to the RSV genome have been 490 
engineered through reverse genetics: the ΔM2-2 deletion which attenuates viral 491 
replication and upregulates antigen expression(83) as well as the ΔNS2 deletion 492 
which reduces viral suppression of host interferon thereby boosting the innate 493 
immune response. RSV MEDI ΔM2-2 strongly reduced viral replication while 494 
inducing a strong primary serum neutralizing antibody as well potent anamnestic 495 
response in RSV-seronegative infants and children(83). Further results from phase I 496 
clinical trials with live-attenuated vaccines are expected. 497 
The only chimeric vaccine candidate, rBCG-N-hRSV, currently in clinical 498 
development is delivered via a BCG strain. BCG has a safe profile in newborns and 499 
infants, induces a Th1 response and allows for combined vaccination against two 500 
major respiratory pathogens: Mycobacterium tuberculosis and RSV. Not only is the 501 
Th1 cellular response important in protecting against lung pathology, inflammation 502 
and viral replication but the vaccine also produces a broad humoral response. The 503 
antigen presented by this vaccine candidate is the RSV N protein(84). Importantly, 504 
this candidate is the only vaccine candidate intended for administration to newborn 505 
infants. 506 
 507 
Monoclonal antibodies 508 
A promising highly potent monoclonal antibody has emerged as a passive 509 
administration strategy to prevent severe RSV infection. MEDI8897, also known as 510 
nirsevimab, was optimized from the human antibody D25 that targets antigenic site 511 
Ø on the Pre-F conformation, which is more neutralization sensitive than the 512 
palivizumab epitope, antigenic site II. Using the YTE technology for extending 513 
antibody half-life, the three-fold increase in half-life of MEDI8897 compared to 514 
palivizumab offers the possibility of passive protection for all infants for an entire 515 
season through a single intramuscular injection. The intended use is for both term 516 
and preterm infants entering their first RSV season. Passive vaccination with an 517 
extended half-life antibody offers an approach to protecting infants that is safe and 518 
may be reasonably priced. Representatives of the pharmaceutical company have 519 
indicated that they expect vaccine-like pricing of MEDI8897. Given the increased 520 
potency, the extended half-life, and the required dose, it is expected that the cost to 521 
protect an infant during the RSV season can be kept relatively low(85). 522 
 523 
Other approaches not in clinical development 524 
Other emerging approaches not yet in clinical development include nucleic acid-525 
based vaccines. Importantly these vaccines induce a T cell response mimicking the 526 
response to live virus infection. Both DNA and messenger RNA (mRNA) vaccines 527 
against RSV have shown promising results in preclinical studies(86). Notably, 528 
through a collaboration with the Bill & Melinda Gates Foundation, an mRNA 529 
technology vaccine platform for HIV and rotavirus has also expanded to include RSV. 530 
 Furthermore, with the first of the palivizumab patents expiring in October 531 
2015 and the last in 2022, there has been active development to produce a 532 
biosimilar in order to provide a low cost RSV preventive intervention.  533 
 534 
Considerations by regulatory agencies and the World Health Organization 535 
The United States Food and Drug Administration (FDA) has articulated that 536 
differences between high income countries (HICs) and LMICs are not particularly 537 
relevant to regulatory decisions, though a bridging study in the US must be 538 
performed if all clinical trials have been performed outside of the US(87). Similarly, 539 
the EMA has indicated that they will allow all trials to take place outside of the EU 540 
for approval. Other considerations in population selection for vaccine trials 541 
mentioned by EMA include: first testing a vaccine candidate in a seropositive before 542 
testing in a seronegative population, testing a maternal vaccine in non-pregnant 543 
women of child-bearing age before testing in pregnant women, and including older 544 
adults with comorbidities in vaccine trials. No particular considerations were 545 
mentioned for population selection in studies for monoclonal antibodies. In October 546 
2017 the EMA released draft guidelines for the clinical evaluation of RSV 547 
prophylactic interventions which included guidance regarding trial design, 548 
assessment of efficacy, and safety(88). The draft guidelines will be revised after a 549 
period of public consultation based on comments and new publications. 550 
 The WHO has recognized the importance of RSV as a global health problem 551 
and has identified the development of RSV vaccines as a priority for the WHO 552 
Initiative for Vaccine Research and for Biological Standardization. WHO recently 553 
developed RSV vaccines preferred product characteristics and research and 554 
development technical roadmap documents(89,90). Further guidance for 555 
development will contribute to adequate policy-making. WHO standardization 556 
activities led to the development and establishment of the first international 557 
standard for antiserum to RSV. Development of Guidelines for evaluation of quality, 558 
safety and efficacy of RSV vaccines has been initiated and will be part of consultation 559 
with regulators, manufacturers and academia in 2018 with the aim of finalizing it in 560 
2019. Further discussion on guiding principles for mAbs is needed before 561 
proceeding with the development of the WHO Guidelines. These and other WHO 562 
standards serve as a basis for setting national regulatory requirements as well as 563 
WHO prequalification.  564 
Finally, the WHO is now performing a surveillance pilot in 14 countries to test the 565 
feasibility of using the Global Influenza Surveillance and Response System platform 566 
for RSV surveillance and it is expected that this pilot will contribute to our 567 
understanding of the RSV disease burden and seasonality in different geographical 568 
regions(91). 569 
 570 
Discussion   571 
Challenges in RSV vaccine design include concerns of ERD post-vaccination, the lack 572 
of definitive immunologic correlates of protection, lack of consensus regarding 573 
clinical endpoints, and limited natural immunity following RSV infection. Despite 574 
these challenges, recent developments such as an understanding of the structural 575 
biology of the RSV fusion protein as well as lessons learned from late-phase vaccine 576 
trial failures have informed the field as it moves forward. Pivotal vaccine trials 577 
should be performed over the course of at least two RSV seasons. 578 
 We attempted to collect data regarding LMIC targets and expected 579 
price for all vaccine candidates, however this information was not publicly available. 580 
The only information obtained regarding expected price was for MEDI8897, though 581 
a more specific estimate than vaccine-like pricing was not available. Given that the 582 
most severe RSV infection occurs in LMICs, information regarding LMIC target 583 
countries and costs will be essential to facilitate access to vaccines worldwide, 584 
especially in areas where the mortality burden is highest. In LMICs the most 585 
important target for vaccine candidates is young children(92). A mechanism should 586 
be introduced to ensure that this information is transparent and available in the 587 
public domain. RSV vaccines and mAbs will be considered as an investment case by 588 
the Global Alliance for Vaccines and Immunization for 2018(93).  589 
Vaccine trials may be used as probe studies to examine the association 590 
between RSV infection and long-term morbidity, a longstanding question in the field. 591 
Long-term follow-up of the RSV prevention trials using palivizumab would now 592 
have provided 20 years of follow-up on respiratory morbidity after RSV prevention 593 
in high-risk infants. Lack of long-term surveillance for airway morbidity in vaccine 594 
trials are missed opportunities to provide novel scientific insights important not 595 
only to understand the pathophysiology but also the long-term vaccine efficacy 596 
against airway morbidity following RSV infection. In addition to wheeze, objective 597 
outcomes, such as lung function measurements including demonstration of 598 
bronchial hyperreactivity and IgE measurements are required in vaccine trials to 599 
fully understand the impact of RSV prevention on asthma development.  600 
 Viral interference, in which RSV inhibits infection by other viruses, is 601 
becoming an increasingly important concept to understand in the context of an 602 
approved RSV vaccine. RSV vaccination may conceivably result in an increased 603 
prevalence of other respiratory viruses. There is evidence supporting viral 604 
interference for influenza vaccination(94,95), for RSV prevention(96,97), and in the 605 
absence of RSV during RSV season(98). It is important for vaccine trials to examine 606 
this phenomenon to better understand the implications of viral interference for an 607 
RSV vaccine. 608 
 This review provides an extensive overview of the 19 vaccine candidates and 609 
mAbs in clinical trials to prevent RSV infection.  RSV vaccine development is moving 610 
rapidly and shows promise to address an unmet global health problem. Vaccines for 611 
all different target populations are in clinical development. One vaccine candidate 612 
and one mAb are in late phase trials (IIb/III) and aim to address the disease burden 613 
in young infants. Despite some recent failures, RSV vaccine candidates and mAbs, 614 
which are in clinical development for all different target populations, hold the 615 
promise that a preventive intervention for RSV is on the horizon. 616 
 617 
618 
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Table 1: Overview of RSV vaccines and mAbs in clinical development 
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O Oral I Cotton rat Jun 2016- 
Dec 2017 
NCT0283
0932 
 
2018? N/A Preclinical:  Systemic 
Anti-F Ab’s  and protection 
against RSV infectio 
in cotton 
rat model(113) 
 
Ad26.RSV.preF Janssen Antigen 
expressed in 
human 
adenovirus 
type 26 
produced in 
PER.C6 
human cell 
line 
Pre-F 
(previous
ly FA2) 
none Ad26 vector 
is replication 
incompetent 
and expresses 
immunogenic 
F antigen 
P IM I Mice, 
cotton 
rats(114) 
Nov 2016 
– Dec 
2018 
NCT0292
6430 
(n=73) 
 
Nov 
2017- 
Mar 2019 
NCT0330
3625 
(n=60) 
N/A N/A PhI: well-tolerated; durable 
humoral and cellular immune 
response for FA2 candidate; 
comparable or higher for preF 
candidate in older adults(115) 
 
Ad26.RSV.preF Janssen Antigen 
expressed in 
human 
adenovirus 
type 26 
produced in 
PER.C6 
human cell 
line 
Pre-F 
(previous
ly FA2) 
none Ad26 vector 
is replication 
incompetent 
but expresses 
immunogenic 
F antigen 
O  IM II Mice, 
cotton 
rats(114) 
Nov 2016 
– Dec 
2018 
NCT0292
6430 
(n-73) 
 
Nov 
2017- 
Mar 
2019NCT
0330362
5 
(n=60) 
Nov 2017- 
Mar 2019 
NCT033036
25 
(n=60) 
 
Dec 2017 –
Jul 2018 
NCT033397
13 
(n=180) 
N/A PhI: well-tolerated; durable 
humoral and cellular immune 
response for FA2 candidate; 
comparable or higher for preF 
candidate in older adults (115) 
 
 
 
SUBUNIT              
GSK RSV F GSK Pre-F 
produced in 
CHO cells 
Pre-F With or 
without 
aluminum 
hydroxide 
Pre-F antigen 
induces 
neutralizing 
antibodies 
which are 
transferred to 
infant 
M IM II Mice, 
cotton 
rats, 
guinea 
pigs, 
cows 
Dec 2014 
–Mar 
2017 
NCT0229
8179 
 
 
Jul 2013-
Mar 2015 
NCT0190
5215 
(n=128) 
(78) 
 
 
 
Mar 2015- 
June 2016 
NCT023604 
75 
(n=507) 
 
Apr 2016 – 
Jun 2016 
NCT027534
13 
(n=102) 
 
Nov 2016 – 
Mar 2018 
NCT029568
37 
(n=406) 
 
Sep 2019 – 
Jan 2021 
NCT031913
83 
Halted due 
to instability 
of pre-F 
antigen 
during 
manufacturi
ng 
 
N/A PhI: safe, RSV-A neutralizing 
Ab titers increased  3.2-4.9x; 
remained high to day 60,  
decreased day 180 & 360 
in healthy men (n=128)(78) 
 
Ph II:  Increased RSV-A 
neutralizing Ab  30 days 
post-vaccination in  
healthy non-pregnant women 
(116) 
DPX-RSV Dalhousie 
University 
DepovaxTM 
delivery in 
100% oil-
based  
SHe DepovaxTM 
or aluminum 
hydroxide 
Depovax 
gives 
controlled 
and 
O IM I Mice, 
cotton 
rats 
May 
2015- 
June 2017 
NCT0247
N/A N/A PhI: Well-tolerated, 
Antigen-specific Ab response 
durable to day 421, 
low immunogenicity with  
platform 
preventing 
release at 
injection site 
prolonged 
exposure of 
antigen and 
adjuvant 
2548 
(n=40) 
 
Jun 2016 
– Dec 
2017 
NCT0283
0932 
(n=66) 
alum adjuvant 
in healthy older adults(117) 
RSV F DS-Cav1 NIH/NIAID/V
RC 
Prefusion 
stabilitized 
trimeric RSVF 
expressed in 
CHO cell line 
Pre-F Alum/ TLR4 
agonist (E) 
Pre-F antigen 
elicits highly 
neutralizing 
antibodies 
against pre-F 
epitopes 
M & O IM I Cotton 
rats, mice, 
calves(11
8), 
macaques
(79) 
Feb 2017- 
Jan 2020 
NCT0304
9488 
(n=100) 
 
N/A N/A Preclinical :induction of high 
neutralizingAbs and 
differential  adjuvant-induced  
enhancement(118) 
 
immunization of mice and  
macaques induces RSV- 
neutralizing Ab many times 
Protective threshold(79) 
LIVE-ATTENUATED/CHIMERIC 
rBCG-N-hRSV Pontificia 
Universidad 
Catolica de 
Chile 
Recombinant 
BCG 
expressing N 
antigen 
N none Paired BCG 
and RSV 
vaccine 
induces Th1 
response 
P ID I Mice 
(119–
122) 
Jun 2017- 
May 2018 
NCT0321
3405 
(n=24) 
N/A N/A Preclinical: Protective T cell 
immune response and  
recruitment of Th1 cells 
(119,120) 
RSV D46 cpΔM2-
2 
Sanofi 
Pasteur/LID/N
IAID/NIH 
M2-2 deletion 
via reverse 
genetics and  
substitutions 
called the “cp” 
mutations. 
whole 
virus 
none Deletion of 
regulatory 
factor M2.2 
causes 
inefficient 
replication 
but high 
immunogenic
ity, further 
attenuation 
with cp 
mutations 
P IN I  Oct 2015- 
May 2017 
NCT0260
1612 
(n=45) 
 
 
N/A N/A N/A 
RSV LID ΔM2-2 
1030s 
Sanofi 
Pasteur/LID/N
IAID/NIH 
M2-2 deletion 
via reverse 
genetics; 
genetically 
stabilized 
with 
temperature 
sensitivity 
mutation 
1030s 
whole 
virus 
none Deletion of 
regulator 
factor M2-
2causes 
inefficient 
replication 
but high 
immunogenic
ity; 
temperature 
sensitive 
mutation at 
position 1030 
of L gene 
P IN I Mice Jun 2016- 
Jul 2017 
NCT0279
4870 
(n=33) 
 
Aug 
2016- 
May 2017 
NCT0295
2339 
(n=33) 
N/A N/A N/A 
RSV ΔNS2 
Δ1313 I1314L 
Sanofi 
Pasteur/LID/N
IAID/NIH 
NS2 and 1313 
deletion via 
reverse 
genetics 
whole 
virus 
none NS2 deletion 
bolsters 
innate 
response, 
Deletion at 
position 1313 
of L protein, 
mutation at 
position 
1314. 
P IN I Mice and 
chimpanz
ees 
Jun 2013-
May 2017 
NCT0189
3554 
 
Aug 
2017- 
May 2019 
NCT0322
7029 
 
N/A N/A N/A 
RSV D46/NS2/N 
ΔM2-2 HindIII 
Sanofi 
Pasteur/LID/N
IAID/NIH 
LID 
backbone, 
substitutions 
in SH gene, 
mutation in 
NS2 and N 
proteins,  
modified M2-
2 deletion, 
based 
on RSV MEDI 
∆M2-2. 
whole 
virus 
none Deletion of 
regulatory 
factor M2.2 
causes 
inefficient 
replication 
but high 
immunogenic
ity  NS2 
deletion 
bolsters 
innate 
response 
P IN I African 
green 
monkeys 
Mar 
2017- 
April 
2018 
NCT0310
2034 
(n=33) 
 
Apr 
2017-Apr 
2019 
NCT0309
9291 
(n=33) 
N/A N/A N/A 
RSV LID cp ΔM2-
2 
Sanofi 
Pasteur/LID/N
IAID/NIH 
M2-2 deletion 
and cp 
mutation 
via reverse 
genetics 
Whole 
virus 
none Deletion of 
regulatory 
factor M2.2 
causes 
inefficient 
replication 
P IN I Chimpanz
ees 
Sep 2016-
Apr 2017 
NCT0289
0381 
(n=17) 
 
N/A N/A N/A 
but high 
immunogenic
ity ; further 
attenuation 
with cp 
mutations 
NCT0294
8127 
Sep 2016- 
Apr 2018 
(n=8) 
MONOCLONAL ANTIBODY (mAb) 
MEDI8897 MedImmune In vitro-
optimized 
human mAb 
with YTE 
mutation in Fc 
N/A N/A Antibody 
targeting site 
Ø of the F 
protein of 
RSV with an 
extended 
half-life 
P IV/IM II Cotton 
rats, 
cynomolg
us 
monkeys 
(85) 
Apr 
2014- Jun 
2015 
NCT0211
4268 
(n=324) 
 
Jan 2015- 
Sep 2016 
NCT0229
0340 
(n=151) 
Nov 2016- 
Nov 2018 
NCT028783
30 
(n=1454) 
 
N/A PhI; well-tolerated,, 
Mean half-life 85-117d; 
time to max concentration  
5-9 days; bioavailability 77% 
in healthy adults (n=136) 
(123) 
      
 
        
 
Legend: N/A: not applicable or not available, IM: intramuscular, ID: intradermal, IN: intranasal, IV: intravenous; ARD: acute 
respiratory disease, PCA: palivizumab-competing antibodies, P: pediatric, M: maternal, O: older adults, SHe: small hydrophobic 
protein ectodomiain; RSV ARD: all symptomatic respiratory disease due to RSV; msLRTD: moderate-severe RSV-associated 
lower respiratory tract disease; NIAID: National Institutes of Allergy and Infectious Diseases; VRC: Vaccine Research Center; 
NIH: National Institute of Health. 

 
Table 2 Overview of vaccines and mAbs by target population 
 
Target Population Vaccine Vaccine type 
Pregnant mothers   
Third trimester RSV F nanoparticle 
(Novavax) 
Nanoparticle 
Third trimester RSV F 
(GSK) 
Subunit 
 RSV F protein (NIH/NIAID/VRC) Subunit 
Pediatric   
6m-5y RSV F nanoparticle 
(Novavax) 
Nanoparticle 
Start 2m Adenovirus 
(GSK) 
Vector 
Start 2-3m Adenovirus 
(Janssen) 
Vector 
 BCG/RSV 
(Pontificia Unversidad Catolica de 
Chile) 
Chimeric 
 RSV D46 cp ΔM2-2  
(Sanofi Pasteur/LID/NIAID/NIH) 
Live-attenuated 
 RSV LID ΔM2-2 1030s  
(Sanofi Pasteur/LID/NIAID/NIH) 
Live-attenuated 
 RSV ΔNS2 Δ1313 I1314L 
(Sanofi Pasteur/LID/NIAID/NIH) 
Live-attenuated 
 RSV D46/NS2/ N/ΔM2-2-HindIII 
(Sanofi Pasteur/LID/NIAID/NIH) 
Live-attenuated 
 RSV LID cp ΔM2-2  
(Sanofi Pasteur/LID/NIAID/NIH) 
Live-attenuated 
 MEDI8897 
(MedImmune) 
Monoclonal antibody 
Older adults   
 RSV F nanoparticle 
(Novavax) 
Nanoparticle 
 RSV BLP 
(Mucosis) 
Nanoparticle 
 MVA (Bavarian Nordic) Vector 
 Adenovirus (Vaxart) Vector 
 Adenovirus (Janssen) Vector 
 DPX-RSV-SH Protein 
(Immunovaccine) 
Subunit 
 RSV F protein 
(NIH/NIAID/VRC) 
Subunit 
Legend: m: months; y: years
Table 3: Expected immune response and previous successes for vaccine & mAbs 
 
Vaccine Target Population Pre-F Immunity* (67) General Immunity Mucosal/Systemic Herd Immunity Previous Vaccine 
Successes 
Nanoparticle       
RSV F Nanoparticle 
(Novavax) 
M Pre-F < post-F Broadly neutralizing 
antibodies 
systemic No No 
RSV F Nanoparticle 
(Novavax) 
O Pre-F < post-F Broadly neutralizing 
antibodies 
systemic Yes No 
RSV F Nanoparticle 
(Novavax) 
P Pre-F < post-F Broadly neutralizing 
antibodies 
systemic Yes No 
RSV BLP 
(Mucosis) 
O & P unclear F confirmation Activation of B & T cells; 
local secretion of 
neutralizing IgA in the 
nose; production of IgG 
neutralizing IgG in the 
blood 
mucosal & systemic Yes No 
Vector       
MVA 
(Bavarian Nordic) 
O Pre-F < post-F B & T cell response; 
antibodies against 5 RSV 
antigens 
systemic Yes IMVAMUNE 
smallpox vaccine 
Adenovirus 
(GSK) 
O Pre-F > post-F B & T cell response; 
neutralizing antibodies 
against F antigen; CD8 T 
cells against F, N and 
M2.1 antigens 
systemic Yes No 
Adenovirus (Vaxart) O Pre-F < post-F B & T cell immunity, 
protection at mucosal 
surface 
mucosal > systemic Yes No 
Adenovirus (Janssen) P Pre-F B & T cells systemic Yes No 
Adenovirus (Janssen) O  Pre-F B & T cells systemic Yes No 
Subunit       
RSV F (GSK) M Pre-F B & T cell response systemic No  
DPX-RSV (Dalhousie 
University) 
O none  systemic No  
RSV F protein 
(NIH/NIAID/VRC) 
O & M Pre-F  systemic No  
Live-attenuated       
BCG/RSV 
s(Pontificia Universidad 
Catolica de Chile) 
P Pre-F & post-F B & T cell response; Th1 
polarized response; 
antibodies against N, F, G 
systemic Yes BCG 
SV D46 cp ΔM2-2 
(Sanofi 
Pasteur/LID/NIAID/NIH) 
P Pre-F & post-F B & T cell response; 
enhanced antibody 
production due to 
increased antigen 
production from M2-2 
deletion 
mucosal & systemic  LAIV 
RSV LID ΔM2-2 1030s 
(Sanofi 
Pasteur/LID/NIAID/NIH) 
P Pre-F & post-F B & T cell response; 
enhanced antibody 
production due to 
increased antigen 
production from M2-2 
deletion 
mucosal & systemic  LAIV 
RSV ΔNS2 Δ1313/I1314L 
(Sanofi 
Pasteur/LID/NIAID/NIH) 
P Pre-F & post-F B & T cell response mucosal & systemic  LAIV 
RSV D46 ΔNS2 N ΔM2-2 
HindIII 
(Sanofi 
Pasteur/LID/NIAID/NIH) 
P Pre-F & post-F  mucosal & systemic   
RSV LID cp ΔM2-2 
(Sanofi 
Pasteur/LID/NIAID/NIH) 
P Pre-F & post-F  mucosal & systemic  LAIV 
Monoclonal Antibody 
MEDI8897 
(MedImmune) 
P N/A N/A N/A No Palivizumab 
 
Legend: Pre-F: prefusion conformation of the RSV F protein; Post-F: postfusion conformation of the RSV F protein; N: RSV 
nucleocapsid protein; F: RSV fusion protein; G: RSV attachment protein; O: older adults; M: maternal; P: pediatric. 
 
Figure 1: RSV burden of disease: Key facts and figures   
 
 
Figure 1 Legend: OR: odds ratio; LRTI: lower respiratory tract infection, RSV: respiratory syncytial virus, HIC: high income 
country, *: compared to children who died with no sepsis or pneumothorax. References: (a)(1) (b)(59) (c)(124) (d)(125) 
(e)(126) (f)(127)
 
Figure 2: Overview of Vaccine candidates and monoclonal antibodies per preventive approach  
 
Legend: For vaccine candidate names listed in gray development has been halted since the last RSV therapeutics review 
performed in 2015(22). Abbreviations: PH I: phase I; PH II: phase II; PH III: phase III.
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